{"entity":{"id":"nct07355205","kind":"trial","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","aka":["FLINN"],"tldr":"A phase 1/2 trial of ipilimumab, nivolumab and nogapendekin alfa inbakicept in lung cancer, run by Washington University School of Medicine, now recruiting.","summary":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07355205 by Washington University School of Medicine, with a registry enrolment figure of 26 participants, started 2026-07-07 and due to reach its primary completion in 2032-07-31. Interventions recorded: Ipilimumab; Nivolumab; Nogapendekin alfa inbakicept. Conditions listed: Non-small Cell Lung Cancer Stage IV; Non-small Cell Lung Cancer Recurrent. Primary outcome: Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants); Incidence of dose-limiting toxicities (DLTs) (Phase Ib participants). Lung eligibility wording from the registry: \"* Histologically or cytologically confirmed, previously untreated or recurrent metastatic NSCLC\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07355205","url":"https://clinicaltrials.gov/study/NCT07355205"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["ipilimumab","nivolumab","nogapendekin-alfa"],"companies":["immunitybio"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07355205","phase":"1/2","setting":"A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)","sponsor":"Washington University School of Medicine","enrolled":26,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07355205/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"nogapendekin-alfa","kind":"drug","name":"Nogapendekin alfa inbakicept","route":"/drugs/nogapendekin-alfa/"}],"company":[{"id":"immunitybio","kind":"company","name":"ImmunityBio","route":"/companies/immunitybio/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}